ArticlePloS one2012
Early clinical and subclinical visual evoked potential and Humphrey's visual field defects in cryptococcal meningitis.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Neurological Sequelae After Paediatric Cryptococcal Meningitis.Journal of fungi (Basel, Switzerland) · 2025Review
- Unusual Presentation of Cryptococcal Meningitis in an Immunocompetent Patient on Hemodialysis.Cureus · 2025Article
- Comparison of mNGS with conventional methods for diagnosis of cryptococcal meningitis: a retrospective study.Scientific reports · 2025Article
- Neuroimaging of Cryptococcal Meningitis in Patients without Human Immunodeficiency Virus: Data from a Multi-Center Cohort Study.Journal of fungi (Basel, Switzerland) · 2023Article
- Review
- Short-term and long-term outcomes in patients with cryptococcal meningitis after ventriculoperitoneal shunt placement.Frontiers in neurology · 2022Article
- Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis.Open forum infectious diseases · 2021Article
- Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study.Wellcome open research · 2019Article
- Disseminated cryptococcosis in a HIV-negative patient: Case report of a newly diagnosed hypertensive adult presenting with hemiparesis.Medical mycology case reports · 2018Article
- Ophthalmic signs in Ugandan adults with HIV-associated cryptococcal meningitis: A nested analysis of the ASTRO-CM cohort.Wellcome open research · 2018Article
- Pattern- and motion-related visual evoked potentials in HIV-infected adults.Documenta ophthalmologica. Advances in ophthalmology · 2017Article
- Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy.Nature reviews. Neurology · 2017Review
- Cryptococcal meningitis initially presenting with eye symptoms in an immunocompetent patient: A case report.Experimental and therapeutic medicine · 2016Article
- Visual loss in HIV-associated cryptococcal meningitis: A case series and review of the mechanisms involved.Southern African journal of HIV medicine · 2015Article
- Visual Disturbance in Patients with Cryptococcal Meningitis: The Road Ahead.Journal of neurosciences in rural practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
Abstract
Cryptococcal induced visual loss is a devastating complication in survivors of cryptococcal meningitis (CM). Early detection is paramount in prevention and treatment. Subclinical optic nerve dysfunction in CM has not hitherto been investigated by electrophysiological means. We undertook a prospective study on 90 HIV sero-positive patients with culture confirmed CM. Seventy-four patients underwent visual evoked potential (VEP) testing and 47 patients underwent Humphrey's visual field (HVF) testing. Decreased best corrected visual acuity (BCVA) was detected in 46.5% of patients. VEP was abnormal in 51/74 (68.9%) right eyes and 50/74 (67.6%) left eyes. VEP P100 latency was the main abnormality with mean latency values of 118.9 (±16.5) ms and 119.8 (±15.7) ms for the right and left eyes respectively, mildly prolonged when compared to our laboratory references of 104 (±10) ms (p<0.001). Subclinical VEP abnormality was detected in 56.5% of normal eyes and constituted mostly latency abnormality. VEP amplitude was also significantly reduced in this cohort but minimally so in the visually unimpaired. HVF was abnormal in 36/47 (76.6%) right eyes and 32/45 (71.1%) left eyes. The predominant field defect was peripheral constriction with an enlarged blind spot suggesting the greater impact by raised intracranial pressure over that of optic neuritis. Whether this was due to papilloedema or a compartment syndrome is open to further investigation. Subclinical HVF abnormalities were minimal and therefore a poor screening test for early optic nerve dysfunction. However, early optic nerve dysfunction can be detected by testing of VEP P100 latency, which may precede the onset of visual loss in CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.